HYTERA
Imagine one day you get a traffic ticket from the police officers with the penalty amount stating: "Stay Home". Recently, movement restriction rules are being enforced in every Emirate in the UAE. In Abu Dhabi, the police officers patrol the streets round the clock and stress the need for people to stay home. They also urge the community to practice social distancing measures and to wear masks and gloves, when stepping out. The effect and efficiency of their work is being guaranteed by Hytera’s Narrowband & Broadband Convergent Communication Solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005013/en/
“During the day, we spread awareness that people should not step out during Sanitization Program and if we spot anyone not wearing a mask, we tell them to put it on. We would give a warning to first-time offenders and impose a Dh 1,000 fine if they're found outside again,” said one of the police officers from the patrols unit. Abu Dhabi Police is responsible for enforcing the compliance with the UAE federal law.
To prevent the spread of Coronavirus, police officers bear an important responsibility for ensuring the public's commitment to the national movement restrictions. The availability of reliable communication services has become an indispensable part to better safeguard citizens both in times of crisis and in normal day-to-day operations.
Abu Dhabi Police have adopted Hytera Narrowband & Broadband Convergent Communication Solution in 2019. Patrol vehicles were equipped with the Hytera Smart devices which support 2G/3G/4G and LTE. This provided the police officers with a converged radio and a smartphone supporting both narrowband and broadband technologies. Smart devices deliver key voice services through the built-in TETRA module, thereby guaranteeing the reliability and security of the Abu Dhabi Police’s daily voice communications. The LTE and Wi-Fi part of the radio provide the broadband data services and application software to support multimedia services, and smart applications used by the Police Enforcement to execute different tasks online, transmit data to the data center and send the required message or safety instructions to the public.
The built-in GPS location functionality of Hytera Smart Devices combined with integrated mapping systems and compasses can upload GPS locations to the Command and Control Center which makes the dispatch task more efficient.
“It is certainly a challenging time for everyone as the pandemic brings significant impact on our life. Many of our users like police and healthcare providers are in the front line of fighting against the virus. As a manufacturer, we believe the secure and reliable communications can make their work more efficient and effective. And as citizens, we all need to practice social distancing to minimize the risk of COVID-19 spreading in the community,” said Stanley Song, Director of the Middle East and North Africa region for Hytera.
For more information, please visit: https://bit.ly/36XU5Dz
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom